ARRB1 and non-small cell lung carcinoma: The recent advances in personalised medicine have resulted in an increasing need for more accurate NSCLC subtyping.8,19,20 Here, we provided evidence that beta-arrestin-1 can effectively differentiate between lung ADC and lung SCC, and demonstrated its usefulness as a diagnostic marker in an IHC panel.